Dear Editor,

We read "Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes" by Saito et al. ([@A5341R1]) with a great interest. This paper shows that raloxifene works in diabetic or non-diabetic hemodialysis patients to reduce bone loss. This was shown by means of significant decrease in NTx and a significant increase in SOS measurements in both treatment groups compared to the un-treated control arms. We would like to draw attention to the possible anti-oxidant role of raloxifene regarding beneficial effects on the bone turnover markers as well as bone mass. The targeted population in this study consisted hemodialysis patients with type 2 diabetes who under a great oxidative stress related to both renal failure and diabetes ([@A5341R2], [@A5341R3]). We have previously demonstrated that women with post-menopausal osteoporosis had lower erythrocyte catalase (CAT) enzyme activity and higher erythrocyte malondialdehyde (MDA) levels ([@A5341R4]). Interestingly, in another study we showed that raloxifene treatment for 3 months significantly enhanced CAT enzyme activity and reduced the MDA levels in women with PMO ([@A5341R5]). Similar anti-oxidant effects of raloxifene were confirmed by others ([@A5341R6]). Although neither discussed nor studied by means of enzymatic parameters, we would like to attract Authors' attention to the potent anti-oxidant effect of raloxifene particularly in this special study population. Significant decrease in N-terminal cross-linking telopeptide of type I collagen (NTx) as well as oxidative stress parameters has been achieved with the use of potent anti-oxidants (lycopene) in patients with PMO ([@A5341R7]). We think the results of this present study should also be admissible regarding the anti-oxidant effects of raloxifene particularly in hemodialysis patients with type 2 diabetes who are under great oxidative stress.
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